Imagine a 3D printer that doesn't just use plastic, but living cells. To make these cells grow into complex shapes like bone or steak, the project adds 'helper' cells—like tiny biological factories—that feed the main cells exactly what they need at the right moment. It's like having a smart construction crew that builds the scaffolding and provides the fuel simultaneously.
Current 3D bioprinting lacks the speed and scale for commercial use and struggles to guide stem cells to form complex, functional tissues naturally.
A bioprinting platform using 'symbiotic materials' consisting of stem cells and engineered helper cells (bacteria/yeast) that automatically trigger growth factors.
If you are a drug developer dealing with the inaccuracy of 2D cell cultures—this project developed a platform for organoids as in-vitro models that provides more predictable and complex living tissue structures for testing.
If you are a food tech company dealing with the difficulty of creating realistic meat textures—this project developed a method to cultivate marbled cultured meat using engineered yeast to promote muscle and fat growth.
If you are a biotech firm dealing with the challenge of growing functional bone tissue—this project developed engineered bacterial helper cells that secrete growth factors to support bone formation.
Based on available project data, specific pricing or cost structures for the platform are not provided.
The project explicitly aims to overcome challenges regarding controlled printability on a commercially viable scale and speed.
Based on available project data, specific licensing terms are not mentioned, though the project has developed proprietary engineered E. coli and yeast strains.
The platform integrates stem cells into a support matrix enriched with helper cells that respond to metabolites secreted by the stem cells during differentiation.
The project period runs from 2022-11-01 to 2027-10-31, suggesting it is currently in the development and testing phase.
The consortium is well-balanced for technology transfer, consisting of 7 partners with a 43% industry ratio (3 companies, including 2 SMEs). The collaboration between 4 universities and industry players across 5 countries suggests a strong pipeline from academic research to commercial application.
Contact IN SRL in Italy
Contact us to explore licensing opportunities for symbiotic bio-inks.
